top of page
Browse by category
Search
Costs of obesity management medications exceeds BMS in less than a year
The cost of taking weekly injections of popular obesity management medications liraglutide (Saxenda) or semaglutide (Wegovy) exceeds that...
Bariatric surgery outperforms GLP-1 diabetes drugs for kidney protection
For patients with type 2 diabetes, obesity and chronic kidney disease, bariatric surgery was associated with a significant decrease in...
Amycretin achieves 13% weight loss within three months with once-a-day tablet
Individuals who received a once-a-day oral weight loss drug, Amycretin developed by Novo Nordisk, lost up to 13% of their body weight...
Strong relationship between the increase in metabolic activity caused by once-daily GLP-1 and the amount of weight lost
A study carried out in St Vincent's University Hospital (SVUH) Dublin, Ireland, challenges the belief that weight-loss medications such...
GLP-1 RAs alone are not enough for individuals to achieve health goals
A group of obesity management professionals led by University College London have acknowledged the promise of the new generation of...
Popularity of GLP-1s among privately insured patients may worsen disparities
Publicly insured US individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than...
Surging US medical costs have employers taking a hard look at the return on investment
Only about half of US employers (52%) say they effectively manage healthcare costs, according to Gallagher's 2024 US Physical & Emotional...
Browse by tag
bottom of page